Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (March 2018)
25 slides from Harrow's investor presentation, Mar 12, 2018
Slide 1: Imprimis Pharmaceuticals March 2018
imprim PHARMACEUTICALS NASDAQ: IMMY MARCH 2018
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private ‘Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements, These statements are based on current expectations of future events. If underlying assum
Slide 3: Pharmaceutical company with 60+ patent filings
Pharmaceutical company with 60+ composition and method patent filings Commercialize as compounded drugs or as candidates for FDA approval through 505(b)(2) spin-outs “80% of revenue is derived from our ophthalmology formulations
Slide 4: Imprimis owns: compounding companies and FDA 505(b)(2) company stakes
Sy IMPRIMIS OWNS: COMPOUNDING COMPANIES IMprimis,, YATES imprimi PHARMACEUTICALS IMPRIMIS IS THE LARGEST SHAREHOLDER OF FDA 505(B)(2) COMPANIES 6 ® elon @urtace
Slide 5: Revenue performance: ophthalmology sales
$6,000 @ REVENUE Ophthalmology Sales ttNon Ophnamelogy Sales PERFORMANCE 000 $4,000 $3,000 $2,000 1000 $0 91-208 G2-20%8 3-208 4-208 t-207— 2-207-207-2007 45 consecutive quarters of = ee Revere okt 3% os 39% 10% 30% a7 Margins expected to hit 60% mone 49% 56% 52% ar 45% 52% 48% 53% rr Decreasing Adj
Slide 6: Imprimis Ophthalmology
Imprimis p, [OPHTHALMOLOGY]
Slide 7: Physician and institution benefits
Imprimis 1YSICIAN AND INSTI ION BENEFITS rance company, pharmacy benefit manager ler of distributor middlemen No formulary rejections, discount cards or rebates No payment submittals, investigations or PBM clawbacks Direct access to drug formulators to meet their needs
Slide 8: Ophthalmology market data
OPHTHALMOLOGY MARKET DATA @ OPHTHALMIC SURGERY @ GLAUCOMA @ DRY EYE OPPORTUNITY IN US FY 2021 GOALS ‘WHERE WE ARE $1 billion drug market ‘“4.6M ocular surgeries and other procedures? Demographic growth in the overall market “6% per yr'® $2 billion drug market 19+ million targeted prescriptions? 4 mi
Slide 9: Formulations for individual patients: glaucoma
FORMULATIONS FOR INDIVIDUAL PATIENTS: ae SS 4 sonia eee | oer, ig hm, 7 es Se pe PROPRIETARY FORMULATIONS INCLUDE: Latanoprost (PA) preservativesree Timotol (BB) + Latanoprost (PA) ‘Timolol (BB) + brimonidine (AA) + dorzolamide (CA) Timotol (BB) + brimonidine (AA) + dorzolamide (CAl) + latanoprost (
Slide 10: Formulations for individual patients: dry eye
FORMULATIONS FOR INDIVIDUAL PATIENTS: TOT PROPRIETARY FORMULATIONS INCLUDE: ‘Chondroitin sulfate + 0.1% cyclosporine Omege-3 AR ‘Omega3 AR/Doxycycline Klarity (chondroitin sulfate + dextran) FROM THE MEDICAL LITERATURE: + Ocular burning/stinging is a major cause of therapy discontinuation for patien
Slide 11: Formulations for office use: PharmaPack
FORMULATIONS FOR OFFICE USE: PHARMAPACK PROPRIETARY FORMULATIONS INCLUDE: Prednisolone acetate + gatifloxacin Prednisolone acetate + gatifloxacin + bromfenac Prednisolone acetate + bromfenac Midazolam + ketamine HCI + ondansetron © OCULAR SURGERY MARKET: + “4.6M ocular surgeries and other procedures
Slide 12: Surface, Park Compounding
G@urtace PARK COMPOUNDING
Slide 13: Eton Pharmaceuticals spin-out
élon ETON PHARMACEUTICALS, INC. SPIN-OUT WHAT IS IT? WHY IS IT IMPORTANT? WHAT IS THE OPPORTUNITY? + 505(b)(2) company with 6 + Imprimis holds passive 27% + 3.5M shares ownership interest pipeline drug assets equity stake in Eton + Royalty opportunity for the + Spun-out of Imprimis June + Mid-single
Slide 14: Surface Pharmaceuticals subsidiary
G@urtace SURFACE PHARMACEUTICALS, INC. SUBSIDIARY WHAT IS IT? 505(b)(2) company with three pipeline drug assets Focus on ocular surface disease market (Dry Eye) Strong management and Board of Directors team with a history of success May pursue spin-off transaction similar to Eton WHY IS IT IMPORTANT
Slide 15: Park Compounding subsidiary
PARK COMPOUNDING 27004-2017 REVENUES PARK COMPOUNDING, INC. SUBSIDIARY WHAT IS WHY IS IT IMPORTANT? WHAT IS THE OPPORTUNITY? + Wholly owned subsidiary + Large, growing and loyal + Add new products and expand + Focused on patientspecific customer base customer base customized drugs + Cash flow genera
Slide 16: Slide 16
Slide 17: Imprimis summary
imprimis ONE OF THE LARGEST + Distupting US ophthalmic drug markets with novel compounded formulations OPHTHALMOLOGY + Ophthalmic Surgery $18 existing drug market COMPOUNDING BUSINESSES + Glaucoma $2B+ existing drug market IN THEUS + DiyEye $28 existing drug market Over 2,000 ophthalmology customers
Slide 18: Company profile
TRADING SYMBOL: NASDAQ: IMMY COMPANY PROFILE PRICE PER SHARE (3-5-2018): $1.99 STOCK PRICE RANGE (52-WEEK): $1.35 - $4.69 AVG. DAILY @4 TRADING VOLUME: 595,000 SHARES INSIDER BENEFICIAL OWNERSHIP: 13% “PARTICIPATION BY CEO, CFO, DIRECTOR IN DEC 2016 FINANCING WWW.IMPRIMISRX.COM MARKET CAP: $41 MILLI
Slide 19: References and Appendix
|_REFERENCES AND APPENDIX
Slide 20: References
@ REFERENCES 4 2. 4 15, Market Scope, LLC, Comprehensive Report on the Global |OL Market (2013, May). Number of LASIK surgeries in the United States from 1996 to 2020. Retrieved February 9, 2016 from hitps:/www statista,com/statistics/271478inumber-ofasik-surgeries-inthe-us/ Imprimis Pharmaceuticals
Slide 21: References
@ REFERENCES 16. 17. 18, 19, 20. 2 22, 23, Glaucoma Research Foundation. Glaucoma Facts and Stats. Retrieved February 9, 2017 from http:/www.glaucoma.org/glaucoma/facts-statistics/glaucoma-facts-and-stats.php Schott, Chis, J.P. Morgan, ““Eye" deally Positioned to Expand the Dry Eye Market..." August
Slide 22: Primer on compounding services
PRIMER ON + When a commercial drug isn’t clinically appropriate, customized drugs can be compounded by highly trained pharmaceutical chemists COMPOUNDING SERVICES Down syndrome cataract surgery patient cannot administer eye drops Ophthalmologist prescribes and administers a compounded combination dr
Slide 23: Published clinical data
PUBLISHED CLINICAL DATA No major intraoperative complications associated with the transzonular injection technique. There were no cases of postoperative endophthalmitis. Rates of infection and inflammation reported in this retrospective review of 1,541 cases from 922 patients receiving a transzonula
Slide 24: SSP Technology
y SSP TECHNOLOGY® v y ALLOWS FOR MIXING 1 lone Act OF ACTIVE DRUGS INTO floxacin HCl rr SUSPENSIONS FOR: Sthmgimt stat meet CATARACT SURGERY = REFRACTIVE SURGERY fs (to
Slide 25: Imprimis contact details
: a 12264 EL CAMINO REAL, SUITE 350 seseee- SAN DIEGO, CA 92130 a m p rl mM | S (858) 704-4040 IR@IMPRIMISPHARMA.COM CHARM ACE eS WWW.|IMPRIMISRX.COM
Imprimis Pharmaceuticals — Investor Presentation (March 2018) on 6ix